Phillip Chan Purchases 3,774 Shares of Cytosorbents (NASDAQ:CTSO) Stock

Cytosorbents Corporation (NASDAQ:CTSO) CEO Phillip Chan acquired 3,774 shares of the company’s stock in a transaction on Tuesday, September 15th. The stock was acquired at an average cost of $6.00 per share, with a total value of $22,644.00. Following the completion of the purchase, the chief executive officer directly owned 100,996 shares in the company, valued at approximately $605,976. This represents a 3.88% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

Cytosorbents Price Performance

Shares of NASDAQ CTSO traded down $0.33 during mid-day trading on Wednesday, hitting $5.73. 4,907 shares of the company’s stock traded hands, compared to its average volume of 7,862. The company has a debt-to-equity ratio of 4.70, a current ratio of 0.66 and a quick ratio of 0.50. Cytosorbents Corporation has a 1 year low of $5.13 and a 1 year high of $20.40. The company’s 50-day moving average is $7.20 and its two-hundred day moving average is $9.83. The company has a market capitalization of $18.06 million, a P/E ratio of -0.99 and a beta of 1.34.

Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.73. Cytosorbents had a negative return on equity of 431.65% and a negative net margin of 48.94%.The company had revenue of $9.63 million during the quarter, compared to analyst estimates of $9.38 million. On average, equities analysts anticipate that Cytosorbents Corporation will post -4.4 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cytosorbents in a report on Monday, July 6th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Cytosorbents has a consensus rating of “Hold” and an average target price of $107.50.

About Cytosorbents

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.